Sobi has announced a streamlining and simplification of the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca.
Tag Archive for: Synagis
Monday morning, Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy. This follows AstraZeneca’s Q2 report released on July 29 that included several other drugs and trials the company is axing.
GSK aims to get the company’s respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly watched late-stage study involving older adults.